Physician profile
Daniel M Walker
NPI 1740615814
$873.98
in general payments reported to CMS, 2019-2025
13 companies · $196 in 2025
The $196 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $174 · 2022: $117 · 2023: $202 · 2024: $185 · 2025: $196.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $583.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $582.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $203.08 | 2021-2025 | Mounjaro, Zepbound |
| Abbvie INC. | $126.71 | 2022-2025 | |
| Abbott Laboratories | $124.85 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Novo Nordisk INC | $81.90 | 2021-2025 | Rybelsus, Ozempic |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $70.62 | 2021-2025 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.67 | 2023-2025 | Jardiance, Tradjenta, Synjardy |
| Bayer Healthcare Pharmaceuticals INC. | $59.35 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $39.71 | 2021-2022 | |
| Pfizer INC. | $25.77 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.08 | 2025 | Caplyta |
| Merck Sharp & Dohme LLC | $20.85 | 2023 | Verquvo, Belsomra, Steglatro |
| Glaxosmithkline, LLC. | $20.22 | 2024 | |
| Inari Medical, INC. | $14.17 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.